Notably, KRT19 has been recently described to protect cancer cells from the immune system, acting in concert with transglutaminase 2 (TGM2) [83] which was also found to be elevated at the mRNA level in Ptenflox/flox prostates of 20-week-old mice (Supplementary Table S3). Here, TGM2 is linked to cancer.